CN113543784A - 用于治疗或预防癌症的喹啉衍生物 - Google Patents

用于治疗或预防癌症的喹啉衍生物 Download PDF

Info

Publication number
CN113543784A
CN113543784A CN201980088810.8A CN201980088810A CN113543784A CN 113543784 A CN113543784 A CN 113543784A CN 201980088810 A CN201980088810 A CN 201980088810A CN 113543784 A CN113543784 A CN 113543784A
Authority
CN
China
Prior art keywords
cancer
formula
pharmaceutically acceptable
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980088810.8A
Other languages
English (en)
Chinese (zh)
Inventor
P·鲍雷蒂
H·埃尔利希
D·谢雷
J·塔泽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Curie
Wittycell
Universite de Montpellier
Original Assignee
Institut Curie
Wittycell
Universite de Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Curie, Wittycell, Universite de Montpellier filed Critical Institut Curie
Priority to CN202411117196.2A priority Critical patent/CN118986981A/zh
Publication of CN113543784A publication Critical patent/CN113543784A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
CN201980088810.8A 2018-12-20 2019-12-19 用于治疗或预防癌症的喹啉衍生物 Pending CN113543784A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411117196.2A CN118986981A (zh) 2018-12-20 2019-12-19 用于治疗或预防癌症的喹啉衍生物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306783.4A EP3669874A1 (en) 2018-12-20 2018-12-20 Quinoline derivatives for use in the treatment or prevention of cancer
EP18306783.4 2018-12-20
PCT/EP2019/086470 WO2020127839A1 (en) 2018-12-20 2019-12-19 Quinoline derivatives for use in the treatment or prevention of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411117196.2A Division CN118986981A (zh) 2018-12-20 2019-12-19 用于治疗或预防癌症的喹啉衍生物

Publications (1)

Publication Number Publication Date
CN113543784A true CN113543784A (zh) 2021-10-22

Family

ID=65200518

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980088810.8A Pending CN113543784A (zh) 2018-12-20 2019-12-19 用于治疗或预防癌症的喹啉衍生物
CN202411117196.2A Pending CN118986981A (zh) 2018-12-20 2019-12-19 用于治疗或预防癌症的喹啉衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411117196.2A Pending CN118986981A (zh) 2018-12-20 2019-12-19 用于治疗或预防癌症的喹啉衍生物

Country Status (11)

Country Link
US (1) US20220071985A1 (https=)
EP (2) EP3669874A1 (https=)
JP (1) JP7570641B2 (https=)
KR (2) KR20210136969A (https=)
CN (2) CN113543784A (https=)
AU (1) AU2019408244B2 (https=)
BR (1) BR112021012132A2 (https=)
IL (1) IL284124B2 (https=)
MA (1) MA54512A (https=)
MX (1) MX2021007178A (https=)
WO (1) WO2020127839A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024109936A1 (zh) * 2022-11-25 2024-05-30 江苏恒瑞医药股份有限公司 一种喹啉胺类化合物晶型及其制备方法
WO2025045123A1 (zh) * 2023-08-30 2025-03-06 江苏正大丰海制药有限公司 用于调节微小rna-124活性的化合物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023126951A1 (en) * 2022-01-03 2023-07-06 Yeda Research And Development Co. Ltd. Inhibitors of autophagy-related protein-protein interactions
WO2025027388A1 (en) 2023-08-01 2025-02-06 Abivax Obefazimod for treatment of ulcerative colitis

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102574835A (zh) * 2009-06-12 2012-07-11 斯皮利寇斯公司 用于治疗癌症的化合物
CN103415290A (zh) * 2010-12-15 2013-11-27 斯皮利寇斯公司 用于治疗aids的化合物
CN103787992A (zh) * 2014-01-21 2014-05-14 华东理工大学 N,n-双取代苯并氮杂环-2-胺类化合物及其用途
CN105612261A (zh) * 2013-01-17 2016-05-25 Abivax公司 作为生物标记物的miRNA-124
WO2017158201A1 (en) * 2016-03-18 2017-09-21 Ratiopharm Gmbh Process for preparing quinolin-2-yl-phenylamine derivatives and their salts
CN107207463A (zh) * 2014-07-17 2017-09-26 Abivax公司 用于治疗炎性疾病的喹啉衍生物
CN107531681A (zh) * 2015-02-23 2018-01-02 Abivax公司 用于治疗和预防病毒感染的新喹啉衍生物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2975034A1 (en) 2014-07-17 2016-01-20 Abivax A quinoline derivative for the treatment of inflammatory diseases and AIDS
JP6474334B2 (ja) 2015-07-30 2019-02-27 株式会社キーエンス 画像検査装置、画像検査方法および画像検査プログラム

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102574835A (zh) * 2009-06-12 2012-07-11 斯皮利寇斯公司 用于治疗癌症的化合物
CN103415290A (zh) * 2010-12-15 2013-11-27 斯皮利寇斯公司 用于治疗aids的化合物
CN105612261A (zh) * 2013-01-17 2016-05-25 Abivax公司 作为生物标记物的miRNA-124
CN103787992A (zh) * 2014-01-21 2014-05-14 华东理工大学 N,n-双取代苯并氮杂环-2-胺类化合物及其用途
CN107207463A (zh) * 2014-07-17 2017-09-26 Abivax公司 用于治疗炎性疾病的喹啉衍生物
CN107531681A (zh) * 2015-02-23 2018-01-02 Abivax公司 用于治疗和预防病毒感染的新喹啉衍生物
WO2017158201A1 (en) * 2016-03-18 2017-09-21 Ratiopharm Gmbh Process for preparing quinolin-2-yl-phenylamine derivatives and their salts

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ASHRAF KAREEM EL-DAMASY等: "Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS *
CAMPOS等: "Long lasting control of viral rebound with a new drug ABX464 targeting Rev – mediated viral RNA biogenesis", RETROVIROLOGY *
JON ZUGAZAGOITIA等: "Current ChallengesinCancerTreatment", CLINICAL THERAPEUTICS *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024109936A1 (zh) * 2022-11-25 2024-05-30 江苏恒瑞医药股份有限公司 一种喹啉胺类化合物晶型及其制备方法
CN120152971A (zh) * 2022-11-25 2025-06-13 江苏恒瑞医药股份有限公司 一种喹啉胺类化合物晶型及其制备方法
WO2025045123A1 (zh) * 2023-08-30 2025-03-06 江苏正大丰海制药有限公司 用于调节微小rna-124活性的化合物

Also Published As

Publication number Publication date
US20220071985A1 (en) 2022-03-10
EP3669874A1 (en) 2020-06-24
JP2022513517A (ja) 2022-02-08
IL284124A (en) 2021-08-31
IL284124B1 (en) 2025-03-01
CN118986981A (zh) 2024-11-22
KR20210136969A (ko) 2021-11-17
MA54512A (fr) 2021-10-27
JP7570641B2 (ja) 2024-10-22
WO2020127839A1 (en) 2020-06-25
AU2019408244A1 (en) 2021-07-08
CA3122912A1 (en) 2020-06-25
KR20250117703A (ko) 2025-08-05
AU2019408244B2 (en) 2025-03-20
IL284124B2 (en) 2025-07-01
BR112021012132A2 (pt) 2021-09-08
MX2021007178A (es) 2021-07-07
EP3897639A1 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
KR102868758B1 (ko) Egfr 돌연변이를 지니는 암을 치료하기 위한 아미노-치환된 헤테로사이클
WO2024197503A1 (en) Tricyclic derivatives as kras inhibitors
TW202136252A (zh) 化合物及其用途
JP2010503717A (ja) Ｅｇｆｒ変異を有する腫瘍を治療するための方法
CN113543784A (zh) 用于治疗或预防癌症的喹啉衍生物
CA2876246A1 (en) Substituted pyrazolone compounds and methods of use
CA3163095A1 (en) Combination therapy involving diaryl macrocyclic compounds
CA2831932A1 (en) Combinations of akt and mek inhibitor compounds, and methods of use
KR20240122783A (ko) Fgfr 저해제 및 kras 저해제를 포함하는 병용 요법
US20230000876A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
HK40053004A (en) Quinoline derivatives for use in the treatment or prevention of cancer
HK40118235A (zh) 用於治疗或预防癌症的喹啉衍生物
CA3122912C (en) Quinoline derivatives for use in the treatment or prevention of cancer
RU2811417C2 (ru) Производные хинолина для применения в лечении или предупреждении рака
US20250042918A1 (en) Compounds
CN118632696A (zh) 包含fgfr抑制剂和kras抑制剂的组合疗法
HK40107546A (zh) 抑制PI3K同工型α的化合物和用於治疗癌症的方法
CN117098537A (zh) 用于癌症治疗的联合疗法
CN117500803A (zh) 用于治疗具egfr突变的癌症的氨基取代杂环
BR122024023622A2 (pt) Uso de um composto derivado de quinolina para tratamento ou prevenção de câncer
BR112019027967A2 (pt) forma b cristalina isolada, composição farmacêutica, método para o tratamento de um distúrbio, método de um composto ou composição, e, processo para produzir forma b cristalina.
NZ617243B2 (en) Combinations of akt and mek inhibitor compounds, and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40053004

Country of ref document: HK